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Abstract 
Background and Aims: Debate exists about whether health professionals (HPs) should advise 
smokers to use nicotine vaping products (NVPs) to quit smoking. The objectives were to 
examine in four countries: (1) the prevalence of HP discussions and recommendations to use an 
NVP; (2) who initiated NVP discussions; (3) the type of HP advice received about NVPs; and (4) 
smoker’s characteristics related to receiving advice about NVPs.  
Design: Cross-sectional study using multivariable logistic regression analyses on weighted data 
from the 2016 ITC Four Country Smoking and Vaping Survey (ITC 4CV1).  
Setting: Four countries with varying regulations governing the sale and marketing of NVPs: 
‘most restrictive’ (Australia), ‘restrictive’ (Canada) or ‘less restrictive’ (England and United 
States).  
Participants: A total of 6615 adult smokers who reported having visited an HP in the last year 
(drawn from the total sample of 12 294 4CV1 respondents, of whom 9398 reported smoking 
cigarettes daily or weekly). Respondents were from the United States (n = 1518), England (n = 
2116), Australia (n = 1046), and Canada (n = 1935).  
Measurements: Participants’ survey responses indicated if they were current daily or weekly 
smokers and had visited an HP in the past year. Among those participants, further questions 
asked participants to report (1) whether NVPs were discussed, (2) who raised the topic, (3) 
advice received on use of NVPs and (4) advice received on quitting smoking.  
Findings: Among the 6615 smokers who visited an HP in the last year, 6.8% reported discussing 
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NVPs with an HP and 2.1% of smokers were encouraged to use an NVP (36.1% of those who had 
a discussion). Compared with Australia (4.3%), discussing NVPs with an HP was more likely in 
the United States [8.8%, odds ratio (OR) = 2.15, 95% confidence interval (CI) = 1.41–3.29] and 
Canada (7.8%, OR = 1.87, 95% CI = 1.26–2.78). Smokers in Australia were less likely to discuss 
NVPs than smokers in England (6.2%), although this was not statistically significant (OR = 1.47, 
95% CI = 0.98–2.20). Overall, the prevalence of HPs recommending NVPs was three times more 
likely in the United States than in Australia (OR = 3.07, 95% CI = 1.45–6.47), and twice as likely 
in Canada (OR = 2.28, 95% CI = 1.06–4.87) than in Australia. Australia and England did not differ 
(OR = 1.76, 95% CI = 0.83–3.74). Just over half (54%) of respondents brought up NVPs 
themselves; there were no significant differences among countries.  
Conclusions: Discussions in Australia, Canada, England, and the United States between smokers 
and health professionals about nicotine vaping products appear to be infrequent, regardless of 
the regulatory environment. A low percentage of health professionals recommended vaping 
products. This was particularly evident in Australia, which has the most restrictive regulatory 
environment of the four countries studied. 
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Introduction 
The current evidence on the effectiveness of nicotine vaping products (NVPs) (e.g. e-cigarettes) 
for smoking cessation is limited [1–3]. Much of the difficulty in establishing a benefit for NVPs 
has do with the dearth of randomized control trials demonstrating a benefit for NVPs as 
cessation aids [4]. While scientists, clinicians and public health organizations have engaged in 
extensive debate about the uncertainty of the possible risks and benefits of NVPs, several 
governments have adopted diverse regulatory approaches [5]. As of 2018, vaping products 
(with or without nicotine) have been banned in 27 countries, nine countries have banned the 
sale of NVPs, and 36 countries permit the sale of NVPs with diverse regulations (e.g. minimum 
age of purchase, advertising and promotion, packaging, product regulation, taxes, etc.) [6].  
Regardless of national (or jurisdictional) legal frameworks of NVPs, they are now a 
popular method for cessation, surpassing other approved cessation aids such as licensed 
nicotine replacement therapy (NRT) and prescription medications in many countries, including 
the United Kingdom, the United States and Canada [7–9]. In 2014, an estimated 6.1 million 
people quit smoking with the help of an NVP in the European Union (EU) [10], and 1.5 million 
adults in Great Britain have stopped smoking cigarettes with the help of NVPs [11]. Evidence 
shows, however, that patterns of NVP use are probably influenced by a country’s regulatory 
environment [12–14]. In countries where NVPs are banned (and enforcement is strong), current 
use of NVPs is generally low [14]. Although NVPs represent a new paradigm for smoking 
cessation by offering smokers nicotine in a way that does not require inhaling combusted 
tobacco smoke, it is unclear how the legal status of NVPs may affect discussions with a health 
professional (HP) in a clinical context. 
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The majority of research on HP–smoker discussions about NVPs comes from cross-
sectional and qualitative surveys of physicians. These studies have indicated that dialogues 
about NVPs have become increasingly frequent in clinical settings [15–19], are generally 
initiated by the patient [16,20,21], and typically do not end in a recommendation to use NVPs, 
apparently because most providers remain neutral or advise against use [20,22–27]. To the best 
of our knowledge, only two studies have examined patient–physician NVP discussions from the 
patient’s perspective [28,29]. One online study in the United States by Berg et al. (2015) found 
that approximately a quarter (27%) of smokers reported having ever talked with their physician 
about NVPs. Among those who had had a discussion, 66% reported that their physician 
recommended NVPs (18% of all 918 smokers) [28]. The second online study from the United 
States by Kollath-Cattano et al. (2016) found that 15% of smokers who saw a physician in the 
prior year reported discussing NVPs with them [29]. Of those who spoke with their physician 
about NVPs, 61% (10% of all 2671 smokers) reported that their physician recommended NVPs 
to help them quit smoking. These studies, therefore, suggest that NVP discussions in clinical 
encounters are not as frequent as physician reports may suggest. Neither of these studies, nor 
those surveying physicians, have considered how regulations on the sale and use of NVPs could 
affect the advice given to smokers. 
Physicians and other HPs (e.g. smoking cessation counsellors, nurses, pharmacists) are 
accessible and reliable sources of support for smoking cessation, and smokers often cite a 
physician’s advice as an important motivator to quit [30,31]. Globally, clinical practice 
guidelines strongly encourage all HPs to identify smokers and offer help to quit. Evidence, 
mainly from the United States, suggests that as conversations about NVPs have increased in the 
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clinical context [15–18], therefore HPs should be prepared to provide a balanced discussion 
about the possibility of using NVPs for smoking cessation. This may be particularly relevant for 
smokers who are seeking advice about NVPs, wanting to try/or already using NVPs to quit 
smoking, or failing repeatedly to quit with medically approved cessation methods [3,4,32,33]. 
For example, recently released National Institute for Health and Care Excellence (NICE) 
guidance in England has recommended that practitioners should give advice to allow an 
informed discussion on using NVPs as a means to quit smoking [34], as they are less harmful 
than combustible cigarettes [35]. However, as clinical practice guidelines in other countries do 
not include such recommendations, HPs may be more hesitant to recommend NVPs to 
smokers. For example, a recent study in the United States found that 50% of 115 surveyed 
physicians reported that although NVPs were a viable harm reduction tool, 51% also stated that 
an absence of regulatory controls by the Food and Drug Administration (FDA) was a major 
concern for them [22]. 
The present study used a large, representative sample of smokers from multiple 
countries with varying regulations governing NVP sales, marketing, possession and use (United 
States, Canada, England and Australia: see Supporting information, Fig. 1) to provide estimates 
of: (1) HP discussions and recommendations for smokers to use an NVP; (2) who initiated NVP 
discussions (HP versus smoking respondent); (3) the type of HP advice received about NVPs; 
and (4) receiving any advice to quit smoking. This study also tested if there were differences in 
estimates throughout the four countries, given that they vary in NVP regulatory policies and 
enforcement. In countries such as Canada and Australia, where nicotine-containing NVPs were 
prohibited to be sold at the time of data collection (possession and use of NVPs without a 
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medical prescription was also prohibited in Australia), HPs may have been less likely to advise 
smokers to use them. Finally, this study also examined smoker’s characteristics related to 
discussing and receiving advice to use NVPs. 
 
Methods 
Sample and procedure 
The International Tobacco Control Four Country Smoking and Vaping Survey Wave 1 (ITC 4CV1) 
Survey [36] is an expansion of the 2002–15 ITC Four Country (ITC 4C) Survey [37]. In brief, the 
ITC 4CV1 Survey consisted of four parallel surveys conducted in Canada, the United States, 
England and Australia, and included adults (aged 18+) who reported to be: currently smoking 
cigarettes (daily, weekly, monthly or less than monthly, but occasionally), currently using an 
NVP (at least weekly) or a former smoker (quit ≤ 2 years). The sample in each country was 
designed to be as representative as possible of cigarette smokers and NVP users (e.g. by age 
and sex), and consisted of re-contacted respondents from the ITC 4C cohort and new 
respondents from online panels (using either probability-based sampling frames or non-
probability opt-in panels, or a combination of these). The survey was completed in English (or 
French when requested in Canada) and took an average of 50 minutes. Data collection occurred 
between July and November 2016. Detailed descriptions of the methods used in each country 
are presented in the ITC 4C and 4CV1 technical reports [36,37], and in the Thompson et al. 
4CV1 methods paper [38]. 
For the current study, respondents were eligible for inclusion if they: (1) were current 
daily or weekly smokers; and (2) had visited an HP in the last year. Monthly or occasional 
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smokers (n = 1,369) and former smokers (n = 1,453) were not included, as discussions about 
NVPs would not be comparable to smokers who are more addicted to nicotine. 
 
Measures 
Demographics, smoking, NVP and health-related variables 
Socio-demographics. Country of residence (used as a proxy for NVP regulatory policy 
environment), sex (male or female), age group (18–24, 25–39, 40–54 or 55+ years), educational 
attainment (low, moderate, high) and annual household family income (low, moderate, high). 
Smoking variables. Respondents were classified as a current daily smoker or a current 
weekly smoker at the time of the survey. Other smoking-related variables included: perceived 
addiction to cigarettes (a little/a lot versus not at all/don’t know), ever tried to quit smoking 
(yes or no), tried to quit smoking in the last year (yes or no) and intentions to quit smoking (in 
the next month/within 6 months versus sometime beyond  6 months/not at all/don’t know). 
NVP variables. Measures related to NVPs included: e-cigarette/vaping device use 
(daily/weekly/occasionally versus not at all/never tried/don’t know), e-cigarettes/vaping make 
quitting smoking easier or harder (yes easier versus no effect/harder versus don’t know), 
opinion of e-cigarettes/vaping (positive versus no opinion/negative versus don’t know), relative 
harm of e-cigarettes/vaping compared to conventional cigarettes/smoking (less harmful versus 
equally harmful/more harmful versus don’t know), e-cigarettes/vaping can improve health 
(would improve health versus no effect/worse/don’t know) and public opinion of e-
cigarettes/vaping (public approves versus neither/disapproves versus don’t know). 
Health variables. Self-reported health and mental health conditions included: 
depression, anxiety, diabetes, chronic lung disease (emphysema, chronic bronchitis or asthma) 
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or cancer (all: yes or no). 
Outcome variables 
Discussion with an HP about NVPs. Respondents were asked: ‘On any visit to a doctor or health 
professional in the last 12 months, did the doctor or health professional talk to you about e-
cigarettes?’ Response options: Yes, no, or don’t know. 
Who brought up the discussion about NVPs. Respondents who reported that they had 
talked to an HP about NVPs were asked: ‘The last time you discussed e-cigarettes with a doctor 
or health professional, did you bring it up or did they?’ Response options: I brought it up, the 
doctor or health professional brought it up, or don’t know. 
Advice about NVPs by the HP. Respondents reporting that they had talked to an HP 
about NVPs were asked: ‘What advice did the doctor or health professional give you about e-
cigarettes?’ Response options: they specifically recommended that I use e-cigarettes, they 
advised me against using e-cigarettes, they didn’t express a view for or against e-cigarettes or 
don’t know. 
Received advice by HP to quit smoking. This was assessed by: ‘On any visit to a doctor or 
health professional in the last 12 months, did you receive any advice to quit smoking?’ 
Response options: Yes, no or don’t know. 
Specific questions and original response options can be found in the ITC 4CV1 Survey 
[39]. All study procedures were approved by the ethics research committee at the University of 
Waterloo (Ontario, Canada), and ethics committees in the US (Medical University of South 
Carolina), England (King’s College London) and Australia (Cancer Council Victoria). 
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Statistical analysis 
Initially, unweighted descriptive statistics of the respondents by country and for the total 
sample were computed.  
Next, cross-sectional weighted estimates were computed for each of the outcomes: (1) 
prevalence of discussions with an HP about NVPs; (2) prevalence of NVP recommendation by an 
HP; (3) who initiated the conversation (HP versus smoker; conditional on having a discussion 
about NVPs); (4) the type of advice received by an HP (conditional on having a discussion about 
NVPs); and (5) advice (yes versus no) received about smoking cessation by the HP.  
[Figure 1 about here] 
Analyses were conducted with separate logistic regressions for each outcome. All 
regression models adjusted for sex, age, smoking status and country. Overall (weighted) 
estimates were presented first, and then country (mean) comparisons were made using 
Australia as the reference country (because it had the strongest NVP regulatory policies, with 
enforcement at the time of the survey). Respondents who refused to answer a question related 
to the outcome variable(s) of interest were excluded from logistic regression analyses (see Fig. 
1). 
For the outcome ‘advice about NVPs by the HP’, within-country ratios were computed 
to determine the proportion of: (1) HPs who recommended NVPs divided by HPs who advised 
against NVPs; and (2) HPs who provided advice for or against NVP use (i.e. formed an opinion) 
divided by HPs with no recommendation either for or against NVPs (i.e. remained neutral). 
Finally, two adjusted binary logistic regression models were estimated to examine which 
respondent characteristics were independently associated with: (1) having a discussion about 
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NVPs (model 1a: yes versus no); and (2) receiving a recommendation to use NVPs (model 1b: 
yes versus no/neutral). All the demographic, smoking, NVP and health variables (described 
above) were included in each model, and are presented in Table 3. Respondents with any 
missing data were removed by listwise deletion from the regression analyses. 
The stratified sampling design (defined by geographic regions within each country) was 
incorporated in all logistic models to address potential design effects. All confidence intervals 
and statistical significance were tested at the 95% confidence level. Analyses were conducted 
using SAS version 9.4. 
 
Results 
Respondents 
Of the 12 294 respondents in the overall main ITC 4CV1 sample, 9398 respondents reported 
smoking cigarettes either daily or weekly at the time of the survey. Among these smokers, 6615 
(70.9%) had visited an HP in the last year, and were therefore eligible for the current study; 
2783 smokers were excluded because they: (i) did not know if they had visited an HP in the last 
year (n = 53); (ii) refused to answer this question (n = 17); or (iii) had not visited an HP in the 
last year (n = 2713). A study inclusion flow-chart is presented in Fig. 1. 
Overall, the sample was on average aged 45.4 years, 51.8% female and the majority 
(87.8%) were daily cigarette smokers. Table 1 presents the unweighted study sample 
characteristics. 
Prevalence of HP discussions and advice about NVPs 
Among all smokers who saw an HP in the last year, 6.8% reported discussing NVPs with an HP 
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and 2.1% of smokers reported that an HP recommended that they use an NVP (Table 2a). 
Content of NVP discussions with an HP 
Among those who discussed NVPs with their HP  (n = 833), 54.0% of smokers reported that they 
brought up the topic and 45.0% reported that their HP did (1.0% did not know/remember). 
Additionally, 36.1% of those who discussed NVPs reported their HP recommended use, 22.1% 
reported being advised against use and 40.4% said their HP remained neutral. Overall, smokers 
from all four countries who reported NVP discussions with their HP were on average more likely 
to report receiving a recommendation to use an NVP compared to a recommendation against 
its use (overall ratio: 1.63; Table 2b). 
[Tables 1 and 2a about here] 
Advice about smoking cessation 
Of those who had visited an HP in the last year and completed the survey question about 
whether they were given smoking cessation advice by an HP (n = 6540), 47.5% reported 
receiving advice about quitting smoking from the HP. Receiving advice to quit from an HP was 
most common in the United States (58.3%) and least common in England (39.5%) (see Table 
2a). Among the smokers who received advice to quit (n = 3317), 12.3% discussed NVPs with an 
HP. Among those who had had a discussion about smoking cessation (n = 724), 37.8% received 
advice to use an NVP, 20.9% of smokers were advised against NVP use and 41.3% of HPs 
remained neutral. 
Country comparisons 
Prevalence estimates of NVP discussions and recommendations. Compared to Australia (4.3%), 
discussing NVPs with an HP was more likely in the United States [8.8%, odds ratio (OR) = 2.15, 
Page 13 of 28 
95% confidence interval (CI) = 1.41–3.29] and Canada (7.8%, OR = 1.87, 95% CI = 1.26–2.78). 
Australia also had a lower proportion of smokers discussing NVPs than in England (6.2%), 
although this was not statistically significant (OR = 1.47, 95% CI = 0.98–2.20). 
[Tables 2b and 3 about here] 
Overall, the prevalence of HPs recommending NVPs was three times more likely in the 
United States (OR = 3.07, 95% CI = 1.45–6.47) than in Australia, and twice as likely in Canada 
(OR = 2.28, 95%    CI = 1.06–4.87) than in Australia. There was no significant difference between 
Australia and England (OR = 1.76, 95% CI = 0.83–3.74). 
Content of discussions. Among those who had discussed NVPs with an HP in the last year 
(n = 833), a higher proportion of smokers in the United States (50.1%) and England (47.2%) 
reported that their HPs initiated the discussion about NVPs than in Canada (40.4%) and 
Australia (39.9%), although these comparisons were not statistically significant. 
Recommendations by HPs to use NVPs was highest in the United States (40.0%) and lowest in 
Australia (28.7%), but again there were no significant differences between countries. The 
United States (33.0%) and Australia (32.7%) also had the highest proportion of HPs advising 
against NVP use, whereas Canada had the lowest (14%), with England in between (20.6%). 
Canadian HPs (50.1%) were significantly more likely to remain neutral (OR = 2.36, 95% CI = 
1.20–4.63) compared to HPs in the United States (25.3%). There were no other significant 
differences between countries (see Fig. 2). 
Among smokers who had received HP advice to quit smoking in the last year and had 
had a discussion about NVPs (n = 715), there were no differences between the countries for the 
positive recommendation to use one; however, Canadian smokers were less likely than 
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American (OR = 0.27; 95% CI = 0.12–0.63) and Australian (OR = 0.33, 95% CI = 0.12–0.95) 
smokers to be advised against using an NVP by an HP. Canadian HPs were also significantly 
more likely to remain neutral compared to American (OR = 3.68, 95% CI = 1.58–8.60) and 
Australian (OR = 3.01, 95% CI = 1.049–8.637) HPs. 
Within-country ratio comparisons among smokers who had had a discussion with an HP 
about NVPs 
HP favorable NVP opinion ratio: recommend NVPs versus advised against use of NVPs. As shown 
in Table 2b, more smokers reported that their HP recommended NVPs as opposed to advising 
against using them in Canada (2.41), the United States (1.21) and England (1.67); but in 
Australia, HPs more often advised against using NVPs (as opposed to advising smokers to use 
them: ratio: 0.88). 
HP opinion provided (recommend versus not recommend) versus no opinion (no advice 
provided). As shown in Table 2b, HPs were reported to have provided advice about NVPs (either 
recommended smokers to use them or advised again use) as opposed to remaining neutral in 
Australia (1.6), England (1.24) and the United States (2.89), whereas a greater proportion of 
Canadian HPs were reported to have remained neutral as opposed to providing any specific 
advice about using an NVP (0.95).  
Smoker characteristics associated with a discussion and advice about NVPs 
Two adjusted logistic regression models estimating the association between smoker’s 
characteristics and discussing NVPs with an HP and recommendation received are presented in 
Table 3. Overall, discussions and NVP recommendations were more common among smokers 
who were: from the United States, Canada or England (compared to Australia), younger, more 
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highly educated, more frequent NVP users, and more positive about NVPs. Both discussions 
about, and recommendations to use NVPs were significantly associated with having received 
advice by an HP in the last year to quit smoking, and with smokers who believed that the public 
approved of NVPs/vaping. 
Discussion 
Although several studies that have surveyed HPs (particularly physician samples) have indicated 
that dialogues about NVPs have become increasingly frequent in clinical settings, findings from 
our study suggest that these discussions in the clinical encounter are not as frequent as HP 
reports have suggested. This is in line with the previous studies that examined NVP discussions 
with samples of smokers [28,29]. Our findings showed that, overall, fewer than 10% of smokers 
reported having a discussion about NVPs with an HP in the last year. Moreover, a number of 
studies have shown that HPs are divided about recommending NVPs for smoking cessation 
[15,19,20,22,26,32]. The results herein have shown that HPs rarely recommended NVPs to 
smokers (only 2% of smokers were encouraged to use an NVP, which was approximately a third 
among those who had a conversation about the topic). Our findings also showed that just over 
half of the reported discussions about NVPs were initiated by the smokers themselves, and not 
by the HP, which may indicate that HPs do not feel entirely comfortable or confident bringing 
up the topic. This has also been found in other studies, where reasons for not advising about 
NVPs have included the HP’s perceived uncertainty about the safety and efficacy of NVPs 
[23,24,40], negative beliefs [20,23–26], lack of knowledge [15,22–25,41], and lack of confidence 
in their own capacity to counsel smokers about NVPs [42]. These cited studies, however, have 
mainly been conducted in the United States using convenience samples, with limited data on 
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common practices in other countries. 
Our study suggests that one of the key reasons why HPs appear hesitant to discuss and 
recommend NVPs is the regulatory environment in which they practice. This was particularly 
evident in our results regarding Australia, where the sale of NVPs is prohibited, and the law is 
enforced. Indeed, fewer Australian smokers reported that an HP had discussed and 
recommended NVPs than smokers in the other three countries. Notably, previous evidence has 
shown that patterns of NVP use by smokers is also likely to be influenced by national NVP 
policies and the strength of these regulations [12–14]. The study by Gravely et al. (2019) 
showed that Australian smokers (and former smokers) had lower rates of NVP use compared to 
other high-income countries, and that the prevalence of NVP use was higher among countries 
where NVPs were widely available for sale, and more commonly used for smoking cessation 
[14]. 
In Canada, a much larger proportion of HPs remained neutral, and did not provide a 
recommendation in favor for or against using an NVP. At the time of the 2016 survey, NVPs 
were not approved for sale, but they were widely available in specialty retail vape shops. In 
November 2016, the Canadian government announced plans to regulate NVPs under the 
Tobacco Act, which would make vaping devices with nicotine legal to sell and purchase (this has 
been in effect since May 2018). This may have been a source of confusion for HPs about the 
role of NVPs for smoking cessation, especially as Canadian clinical practice guidelines do not 
currently recommend NVPs as a quit aid (even though NVPs are the most popular quit assist 
method reported by smokers in Canada [9]). Therefore, HP advice in Australia and Canada was 
probably strongly influenced by national regulatory policies, the absence of NVP 
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recommendation in clinical guidelines, the level of availability of NVPs on the open market, and 
the relative popularity of NVPs among smokers. 
One interesting finding in this study was that smokers in England did not report a higher 
proportion of NVP discussions or recommendations. This is striking, given that at the time of 
the survey, the Royal College of Physicians (RCP) of London, England [43] and Public Health 
England (PHE) [44] strongly supported the notion that NVPs should be widely promoted as a 
substitute for smoking. PHE published a joint-position statement in July 2016 with other UK 
public health organizations supporting NVPs as a cessation tool (or at least that HPs should 
encourage smokers to completely switch to NVPs) [45]. The unexpectedly low level of 
discussions of NVPs with HPs in England may be partly explained by the positions of the British 
Medical Association [46] and the World Health Organization (WHO) [47], which have not 
actively supported NVPs to be used for cessation in the absence of strong data about their 
safety and efficacy. A 2016 report by the WHO stated that there is not enough research to 
quantify the relative risk of NVPs over combustible products [47], and WHO has previously 
urged countries to restrict the sale, promotion and use of electronic cigarettes [48]. 
Additionally, some recent reviews have also demonstrated the inconclusive evidence about the 
health risks associated with NVPs use [49–51]. Therefore, our data may be indicating that HPs in 
England (and in the other countries) may be conflicted about the role of NVPs in smoking 
cessation due to the opposing positions of various NGO and public health organizations. 
Another explanation may be that smokers in England are turning to sources other than an HP 
for advice about NVPs, such as online sources (e.g. product websites, social media etc.), retail 
shops, friends, or NVP packaging instructional pamphlets. This should be further explored. 
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In addition to the country effects found in this paper, the results also showed that NVP 
discussions and recommendations were more common among smokers who were: younger, 
more highly educated, advised to quit smoking at the time of their HP visit, more frequent NVP 
users, more positive about NVPs, and more likely to perceive that the public approved of NVPs. 
Similar to other studies that have shown that physicians were more likely to recommend NVPs 
if they normally assess the smoking status of their patients [18,21], HPs in this study were also 
more likely to discuss and recommend NVPs to smokers if the respondents reported that they 
had received advice about quitting smoking in the last year. Some research has shown that 
patient’s questions about NVPs do not always directly relate to smoking cessation specifically, 
and can more generally be about the harm and safety of NVPs (including side effects, nicotine 
health risks and addiction issues). For example, one online study of licensed HPs from various 
disciplines found that half of providers reported having discussed vaping as a harm reduction 
option, while 26% discussed vaping as a quit aid [19]. Our study suggests that HPs who are 
offering direct smoking cessation advice to their patients (and perhaps more regularly assess 
smoking status and cessation) may be more willing to recommend NVPs as a quit smoking aid. 
Additionally, other studies have shown that NVPs are more frequently used among those who 
are younger and have a higher education and income [7,52–54]; therefore, HPs may be tailoring 
their discussions and advice about NVPs based on the smoker’s demographic profile (e.g. to 
those who may be more willing to try them). 
While this cross-sectional study has many strengths (e.g. a large population-based 
sample of smokers from four countries), the results should be interpreted with caution, owing 
mainly to issues of temporality and recall bias. For example, smoker’s perceptions and beliefs 
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about NVPs at the time of the survey may not have been the same when they visited their HP. 
Similarly, we are unable to determine if HP advice to use NVPs was associated with resultant 
vaping initiation as a method to stop smoking. Furthermore, the findings probably 
underestimate the life-time prevalence of discussions between an HP and smokers, as the time-
frame for reporting NVP discussions was limited to the prior year (in order to reduce recall 
bias). Finally, the lack of significant findings for some analyses may be due to statistical power 
issues resulting from low prevalence of some key outcomes (i.e. discussions of NVPs with a HP 
was < 10% of the initial sample).  
Conclusions 
Despite the need for more evidence on their efficacy and long-term safety, NVPs are now a 
more popular method for cessation than licensed NRT and prescription stop-smoking 
medications in many countries [7–9]. In light of this, HPs should be prepared to provide 
balanced information about NVPs, particularly to smokers who are unable to stop smoking with 
approved cessation therapies, and for those who are requesting guidance regarding NVPs as a 
smoking cessation aid [4]. Overall, the results from this study have shown that discussions 
between smokers and HPs about both quitting smoking, and the possible role NVPs could play 
as a cessation aid, were infrequent in the four countries in 2016. This may represent a lost 
opportunity for encouraging quitting smoking by providing a potentially attractive option to 
help smokers to quit. Some country differences were evident, particularly in Australia, which 
has the strictest regulatory environment, and where HPs were less likely to discuss and endorse 
NVPs.
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Figure 1. Study Inclusion Flow Diagram 
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Figure 2. Health professional (HP) advice about vaping products (VPs) among smokers who had a discussion with a HP about VPs 
in the last year (n=831). 
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Table 1 Characteristics of the study sample (unweighted). 
 
 Australia Canada England United States Total 
Sample 
Characteristic, n (%) n = 1046 (15.8) n = 1935 (29.2) n = 2116 (32.0) n = 1518 (23.0) N = 6615 
Sex Male 496 (47.4) 863 (44.6) 1071 (50.6) 757 (49.9) 3187 (48.2) 
Female 550 (52.6) 1072 (55.4) 1045 (49.4) 761 (50.1) 3428 (51.8) 
Age Mean age 51.1 43.8 43.7 45.8 45.4 
Age group 18–24 23 (2.2) 368 (19.0) 435 (20.6) 300 (19.8) 1126 (17.0) 
25–39 171 (16.4) 442 (22.8) 434 (20.5) 367 (24.2) 1414 (21.4) 
40–54 397 (38.0) 564 (29.2) 586 (27.2) 238 (15.7) 1785 (27.0) 
55+ 455 (43.5) 561 (29.0) 661 (31.2) 613 (40.4) 2290 (34.6) 
Educational level Low 356 (34.0) 586 (30.3) 631 (29.8) 458 (30.2) 2031 (30.7) 
Moderate 420 (40.2) 871 (45.0) 866 (40.9) 578 (38.1) 2735 (41.4) 
High 289 (24.8) 466 (24.1) 587 (27.7) 482 (31.8) 1794 (27.1) 
No answer 11 (1.1) 12 (0.6) 32 (1.5) 0 (0.0) 55 (0.8) 
Income Low 228 (21.8) 441 (22.8) 501 (23.7) 476 (31.4) 1646 (24.9) 
Moderate 271 (25.9) 297 (15.4) 636 (30.1) 375 (24.7) 1579 (23.9) 
High 478 (45.7) 1060 (54.8) 814 (38.5) 652 (43.0) 3004 (45.4) 
Not stated 69 (6.6) 137 (7.1) 165 (7.8) 15 (1.0) 386 (5.8) 
Smoking status Daily 999 (95.5) 1644 (85.0) 1835 (86.7) 1332 (87.8) 5810 (87.8) 
Weekly 47 (4.5) 291 (15.0) 281 (13.3) 186 (12.3) 805 (12.2) 
Addicted to cigarettes Not at all 23 (2.2) 124 (6.4) 171 (8.1) 82 (5.4) 400 (6.1) 
Yes, somewhat 343 (32.8) 742 (38.4) 909 (43.0) 627 (41.3) 2621 (39.6) 
Yes, very much 674 (64.4) 1048 (54.2) 1009 (47.7) 792 (52.2) 3523 (53.3) 
Don’t know 6 (0.6) 20 (1.0) 27 (1.3) 14 (0.9) 67 (1.0) 
Ever tried to quit Yes 933 (89.2) 1661 (85.8) 1693 (80.0) 1229 (81.0) 5516 (83.4) 
smoking      
Tried to quit smoking Yes 
(≤ 12 months) 
591 (56.5) 1182 (61.1) 1076 (50.9) 831 (54.8) 3680 (55.7) 
Intention to quit Within 1 month 139 (13.3) 247 (12.80 265 (12.5) 219 (14.4) 870 (13.2) 
smoking 1–6 months 287 (27.4) 563 (29.1) 524 (24.8) 367 (24.2) 1741 (26.3) 
Beyond 6 months 353 (33.8) 695 (35.9) 666 (31.5) 473 (31.2) 2187 (33.1) 
No plan 153 (14.6) 232 (12.0) 463 (21.9) 290 (19.1) 1138 (17.2) 
Don’t know 114 (10.9) 196 (10.1) 195 (9.2) 166 (10.9) 671 (10.1) 
E-cigarette use Daily use 57 (5.5) 210 (10.9) 246 (11.6) 302 (19.9) 815 (12.3) 
Weekly use 50 (4.8) 264 (13.6) 189 (8.9) 236 (15.6) 739 (11.2) 
< weekly 39 (3.7) 152 (7.9) 203 (9.6) 89 (5.90) 483 (7.3) 
< monthly 122 (11.7) 434 (22.4) 444 (21.0) 170 (11.2) 1170 (17.7) 
Not at all 248 (23.7) 311 (16.1) 437 (20.7) 355 (23.4) 1351 (20.4) 
Never tried 530 (50.7) 564 (29.2) 597 (28.2) 366 (24.1) 2057 (31.1) 
E-cigarettes make A lot easier 127 (12.1) 251 (13.0) 291 (13.8) 222 (14.6) 891 (13.5) 
quitting smoking A bit easier 281 (26.9) 767 (39.6) 851 (40.2) 496 (32.7) 2395 (36.2) 
easier or harder No effect 190 (18.2) 359 (18.6) 408 (19.3) 299 (19.7) 1256 (19.0) 
A bit harder 55 (5.3) 145 (7.5) 158 (7.5) 128 (8.4) 486 (7.4) 
A lot harder 34 (3.3) 69 (3.6) 79 (3.7) 64 (4.2) 246 (3.7) 
Don’t know 351 (33.6) 330 (17.1) 318 (15.0) 297 (19.6) 1296 (19.6) 
Opinion of vaping Very positive 38 (3.6) 57 (3.0) 74 (3.5) 144 (9.5) 313 (4.7) 
Positive 125 (12.0) 325 (16.8) 413 (19.5) 284 (18.7) 1147 (17.3) 
No opinion 860 (40.9) 860 (44.4) 962 (45.5) 597 (39.3) 2847 (43.0) 
Negative 172 (16.4) 406 (21.0) 381 (18.0) 271 (17.9) 1230 (18.6) 
Very negative 67 (6.4) 120 (6.2) 165 (7.8) 100 (6.6) 452 (6.8) 
Don’t know 208 (19.9) 151 (6.9) 109 (5.2) 105 (6.9) 573 (8.7) 
Harm: e-cigarettes Much less 201 (19.2) 417 (21.6) 474 (22.4) 292 (19.2) 1384 (20.9) 
compared to Somewhat less 348 (33.3) 768 (39.7) 928 (43.9) 536 (35.3) 2580 (39.0) 
conventional Equally 173 (16.5) 412 (21.3) 352 (16.6) 376 (24.8) 1313 (19.9) 
cigarettes Somewhat more 19 (1.8) 58 (3.0) 65 (3.1) 55 (3.6) 197 (3.0) 
Much more 7 (0.7) 26 (1.3) 30 (1.4) 35 (2.3) 98 (1.5) 
Don’t know 297 (28.4) 253 (13.1) 267 (12.6) 218 (14.4) 1035 (15.7) 
     (Continue
s) 
 
Table 1 (Continued)  
  Australia Canada England United States Total 
Sample 
Characteristic, n (%)  n = 1046 (15.8) n = 1935 (29.2) n = 2116 (32.0) n = 1518 (23.0) N = 6615 
Public opinion of Strongly approves 6 (0.6) 26 (1.3) 23 (1.1) 75 (4.9) 130 (2.0) 
e-cigarettes Somewhat approves 23 (2.2) 65 (3.4) 92 (4.4) 127 (8.4) 307 (4.6) 
 Neither 112 (10.7) 183 (9.5) 323 (15.3) 182 (12.0) 800 (12.1) 
 Somewhat disapproves 408 (39.0) 687 (35.5) 1017 (48.1) 492 (32.4) 2604 (39.4) 
 Strongly disapproves 472 (45.1) 947 (48.9) 631 (29.8) 600 (39.5) 2650 (40.1) 
 Don’t know 24 (2.3) 26 (1.3) 30 (1.4) 38 (2.5) 118 (1.8) 
Comorbidities (yes) Depression 472 (45.1) 947 (48.9) 631 (29.8) 600 (39.5) 2650 (40.1) 
 Anxiety 24 (2.3) 26 (1.3) 30 (1.4) 38 (2.5) 118 (1.8) 
 Diabetes 300 (28.7) 446 (23.1) 572 (27.0) 389 (25.6) 1707 (25.8) 
 Cancer 240 (22.9) 483 (25.0) 464 (21.9) 406 (26.8) 1593 (24.1) 
 Lung disease 100 (9.6) 167 (8.6) 172 (8.1) 191 (12.6) 630 (9.5) 
Data are unweighted. Row percentages are reported within country cells and total percentages are presented for the total sample that were eligible for the study and had 
complete data. Chronic lung disease/illness: asthma, emphysema or chronic bronchitis. 
Table 2a Prevalence estimates of HP advice to quit smoking, discussions with an HP about NVPs, and the recommendation to use an 
NVP by an HP among smokers from four countries with differing NVP regulatory policiesb. 
 
Prevalence estimates of HP 
advice to quit smoking 
(6540) 
 
Prevalence estimates 
ofNVP discussions with an 
HP (6566) 
 
Prevalence estimates ofNVP 
recommendations by an HP 
(6603)a 
 
% 95% CI 
 
% 95% CI 
 
% 95% CI 
Australia 50.4% 46.64–54.11  4.3 2.88–5.78  1.1 0.54–2.10 
Canada 47.1% 44.48–49.75  7.8 6.49–9.13  2.4 1.77–3.25 
England 39.5% 36.81–42.17  6.2 5.03–7.37  1.9 1.32–2.64 
United States 58.3% 54.55–61.90  8.8 6.93–10.74  3.2 2.36–4.34 
Total 47.5% 45.93–49.09  6.8 6.08–7.55  2.1 1.70–2.56 
Country Comparisons    OR 95% CI  OR 95% CI 
Canada versus Australia – –  1.87 1.26–2.78  2.28 1.06–4.87 
England versus Australia – –  1.47 0.98–2.20  1.76 0.83–3.74 
United States versus Australia – –  2.15 1.41–3.29  3.07 1.45–6.47 
Australia is the reference country for comparisons for nicotine vaping product (NVP) discussions and recommendations because it has the strictest NVP 
regulatory policies and enforcement environment. CI = confidence interval; HP = health professional; NVP = nicotine vaping product; OR = odds ratio. 
aRespondents who reported that they did not have a discussion with a health professional were coded as ‘not recommended an NVP/e-cigarette’. bThe data 
are based on smoking respondents who reported that they visited an HP in the last year (prior to the survey). 
 
Table 2b Nicotine vaping product (e-cigarette) discussions, and their content, between health professionals and smokers within last year. 
Outcome Australia (reference country)  Canada England United States Overall 
 
On any visit to a doctor or health professional in the last 12 months, did the doctor or health professional talk to you about e-cigarettes? (n = 6566) 
Yes (n = 833) 4.3% 7.8% 6.2% 8.8% 6.8% 
No (n = 5683) 95.2% 91.7% 92.8% 90.2% 92.5% 
Don’t know (n = 50) 0.5% 0.5% 1.0% 1.0% 0.7% 
The last time you discussed e-cigarettes with a doctor or health professional, did you bring it up or did they? (n = 833) 
I brought it up (n = 463) 57.4% 57.9% 51.8% 49.5% 54.0% 
HP brought it up (n = 355) 39.9% 40.4% 47.2% 50.1% 45.0% 
Don’t know (n = 15) 
What advice did the doctor or health professional give you about e-cigarettes? (n = 831)a 
2.7% 1.7% 1.0% 0.3% 1.0% 
HP recommended that I use e-cigarettes (n = 350) 28.7% 33.6% 34.4% 40.0% 36.1% 
HP advised me against using e-cigarettes (n = 197) 32.7% 13.9% 20.6% 33.0% 22.1% 
HP didn’t express a view for or against e-cigarettes (n = 274) 37.3% 50.1% 44.2% 25.3% 40.4% 
Don’t know (n = 10) 1.3% 2.4% 0.8% 1.7% 1.5% 
Within-country ratio comparisons (among patients who had a discussion with their HP about e-cigarettes, n = 831a)     
Favorable e-cigarette opinion ratio: recommend e-cigarettes versus advised against use of e-cigarettes 0.88 (28.7/32.7) 2.41 (33.6/13.9) 1.67 (34.4/20.6) 1.21 (40.0/33.0) 1.63 (36.1/22.1) 
Opinion (recommend versus not recommend) versus no opinion 1.6 (61.4/37.3) 0.95 (47.5/50.1) 1.24 (55.0/44.2) 2.89 (73.0/25.3) 1.44 (58.2/40.4) 
Data are weighted; Estimates control for sex, age and country. ‘Don’t know’ responses were included in the ‘No’ response options for comparisons for the outcome: discussion about e-cigarettes (no discussion) and as ‘HP didn’t express 
a view for or against e-cigarettes’ for the outcome advice about using e-cigarettes, and were excluded for the outcome ‘who raised the topic (n = 15)’. aTwo respondents refused to answer the question about HP e-cigarette 
recommendation and were excluded. 
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Table 3 Model 1: Adjusted logistic regression analyses examining smoker’s characteristics associated with a discussion about NVPs with a 
health professional, and with a recommendation to use an NVP. 
 
Model 1a: talked to a health professional about NVPs 
(e-cigarettes) (n = 6385) Yes (n = 802) versus no (5583) 
 
Model 1b: received advice to use an NVP (e-cigarette) (n = 6383) 
Yes (n = 333) versus no/no opinion/no discussion (n = 6050) 
 
 
95% CI 
     
95% CI 
 
Variables % OR Lower bound Upper bound P-value 
 
% OR Lower bound Upper bound P-value 
Country 
          
Canada 3.1% 2.41 1.55 3.75 < 0.001  0.5% 3.25 1.69 6.25 < 0.001 
England 2.8% 2.22 1.42 3.47 < 0.001  0.3% 2.09 1.05 4.17 0.037 
United States 3.6% 2.82 1.75 4.55 < 0.0001  0.7% 4.06 2.04 8.08 < 0.0001 
Australia 1.3% Reference    0.2% Reference    
Sex           
Male 3.6% 1.75 1.35 2.27 < 0.0001  0.5% 1.36 0.90 2.04 0.142 
Female 2.1% Reference    0.3% Reference    
Age (years)           
18–24 4.7% 2.58 1.67 3.98 < 0.0001  1.0% 4.96 2.36 10.42 < 0.0001 
25–39 3.4% 1.82 1.22 2.71 0.003  0.5% 2.47 1.29 4.73 0.006 
40–54 2.8% 1.51 1.05 2.17 0.027  0.5% 2.34 1.21 4.54 0.012 
55+ 1.9% Reference    0.2% Reference    
Educational level 
Low 2.5% 0.56 0.39 0.80 0.001 0.4% 0.60 0.36 1.00 0.048 
Moderate 2.4% 0.52 0.39 0.70 < 0.0001 0.3% 0.48 0.31 0.76 0.002 
Not stated 6.0% 1.37 0.40 4.68 0.611 2.0% 3.08 0.52 18.36 0.216 
High 4.5% Reference   0.7% Reference    
Income          
Low 2.5% 0.79 0.55 1.13 0.198 0.3% 0.51 0.29 0.88 0.015 
Moderate 2.6% 0.84 0.60 1.19 0.337 0.4% 0.77 0.46 1.30 0.335 
Not stated 1.8% 0.58 0.29 1.14 0.114 0.2% 0.42 0.14 1.27 0.124 
High 3.1% Reference   0.5% Reference    
Smoking status          
Daily 2.6% 0.73 0.49 1.08 0.114 0.4% 1.49 0.78 2.82 0.225 
Weekly 3.6% Reference   0.3% Reference    
Addicted to cigarettes 0.968 
Yes 2.9% 2.01 1.24 3.25 0.005 0.4% 1.01 0.58 1.75 
somewhat/         
very much         
Not at all 1.4% Reference   0.4% Reference   
Attempted to quit smoking in the last 12 months 
Yes 2.8% 1.03 0.68 1.57 0.884 0.4% 0.92 0.47 1.79 0.804 
No 2.7% Reference   0.4% Reference    
Intention to quit smoking 
≤ 6 months 3.5% 1.53  1.17 2.02 0.002 0.4% 1.03 0.69 1.53 0.885 
> 6 months/ 
no plan 
2.3% Reference 0.4% Reference 
Received advice by HP to quit smoking 
Yes 8.4% 9.30 6.36 13.60 < 0.0001 1.5% 12.11 6.59 22.28 < 0.0001 
No/don’t 1.0% Reference   0.1% Reference    
know          
E-cigarette use          
Daily 10.4% 5.44 3.72 7.95 < 0.0001 1.5% 4.24 2.41 7.45 < 0.0001 
Weekly 8.7% 4.47 3.02 6.64 < 0.0001 0.7% 2.02 1.12 3.66 0.020 
< Weekly 3.1% 1.48 1.04 2.10 0.029 0.3% 0.96 0.53 1.74 0.898 
Not at all/ 2.1% Reference   0.4% Reference    
never tried          
         (Continues) 
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Table 3 (Continued) 
  
Model 1a: talked to a health professional about NVPs 
(e-cigarettes) (n = 6385) Yes (n = 802) versus no (5583) 
 
 
Model 1b: received advice to use an NVP (e-cigarette) (n = 6383) 
Yes (n = 333) versus no/no opinion/no discussion (n = 6050) 
 
95% CI 
     
95% CI 
 
Variables % OR Lower bound Upper bound P-value 
 
% OR Lower bound Upper bound P-value 
NVPs make quitting smoking easier or harder 
At least a bit 3.4% 1.12 0.79 1.59 0.524 0.6% 1.65 0.95 2.87 0.075 
easier          
Don’t know 1.5% 0.47 0.29 0.77 0.003 0.2% 0.44 0.13 1.49 0.186 
No effect/ 3.1% Reference   0.4% Reference    
harder          
Opinion of vaping 
Positive 4.3% 1.93 1.39 2.69 < 0.0001 0.9% 3.31 1.99 5.52 < 0.0001 
Don’t know 5.3% 2.38 1.22 4.65 0.011 1.4% 4.80 1.25 18.39 0.022 
No opinion/ 2.3% Reference   0.3% Reference    
negative          
Harm: NVPs compared to regular cigarettes 
Less harmful 2.2% 0.55 0.38 0.80 0.002 0.4% 1.38 0.77 2.44 0.277 
Don’t know 3.3% 0.83 0.46 1.52 0.546 0.8% 2.78 0.97 7.94 0.057 
Equally 3.9% Reference   0.3% Reference    
harmful/          
more          
harmful          
NVPs effect on health 
Improve (a 3.1% 1.09 0.71 1.68 0.684 0.4% 1.15 0.63 2.12 0.649 
lot/little)          
Don’t know 1.9% 0.67 0.38 1.17 0.155 0.3% 0.81 0.34 1.93 0.628 
No effect/ 2.8% Reference   0.4% Reference    
worsen          
Public’s opinion about NVPs 
Approve 4.1% 1.52 1.12 2.07 0.008 1.1% 2.47 1.54 3.97 < 0.001 
Don’t know 1.7% 0.62 0.35 1.09 0.096 0.1% 0.21 0.06 0.77 0.019 
Neither 2.7% Reference   0.4% Reference    
approve or          
disapprove          
Depression          
Yes 3.0% 1.15 0.82 1.62 0.414 0.5% 1.40 0.87 2.26 0.166 
No 2.6% Reference   0.4% Reference    
Anxiety          
Yes 2.1% 0.69 0.48 1.00 0.048 0.2% 0.48 0.29 0.81 0.006 
No 3.0% Reference   0.5% Reference    
Diabetes          
Yes 4.4% 1.75 1.07 2.85 0.026 0.7% 1.78 0.93 3.40 0.080 
No 2.6% Reference   0.4% Reference    
Cancer          
Yes 6.7% 2.61 1.18 5.77 0.018 0.2% 0.48 0.14 1.69 0.254 
No 2.7% Reference   0.4% Reference    
Lung disease          
Yes 3.5% 1.33 0.85 2.07 0.214 0.8% 2.02 1.09 3.73 0.026 
No 2.7% Reference   0.4% Reference    
‘Don’t know’ responses were included in the ‘No’ response options for some variables. OR = odds ratio; CI = confidence interval; NVP = nicotine vaping product. 
Supplemental Figure 1. Summary and depiction of the general level of national nicotine vaping products 
(NVP) regulatory policies for the sale and marketing of e-cigarettes that were in place prior to and during 
data collection for this study (July to November 2016). 
Most restrictive NVP regulatory policies with strong enforcement 
• Illegal to sell NVPs; this law is strongly enforced.  
• NVPs are not widely available in retail stores. 
Australia 
• The possession/use of NVPs without a prescription is banned throughout Australia. One state 
(Western Australia) has banned the sale of all vaping devices regardless of nicotine content. Many 
jurisdictions apply similar restrictions on public vaping as for smoking. - Therapeutic Goods Administration, 2017 
 
Restrictive NVP regulatory policies with weak enforcement 
• NVPs not approved for sale, but are widely available (including in specialty retail locations) due to 
weak enforcement of the law. 
Canada 
• Vaping device manufacturers not permitted to make cessation or medical/ therapeutic claims. Over 
the past decade vaping specialty stores have increased their selection of devices and e-liquids with a 
range nicotine strengths.  Advertising NVPs not permitted, although not strongly enforced.  - Health Canada, November 2016 
 
Less restrictive NVP regulatory policies 
• Legal to sell NVPs in several retails locations, with country-specific regulations. 
England* 
United States** 
*England: Cross border NVP advertising banned, but local advertising permitted, including: outdoor 
billboards/posters, public transport posters, point of sale, leaflets, and direct mail. Local advertisements were 
required to meet the following criteria:  
o should not appeal to children/youth,  
o should be socially responsible,  
o should not show images that look like ordinary cigarettes, and 
o not permitted to make cessation claims or medical/ therapeutic claims.  
• NVP labels must follow EU chemical labelling laws. - UK Tobacco and Related Products Regulations 2016 
**US:  NVP advertising and sales permitted in all channels. 
• Labeling and advertisements not permitted to make cessation claims or other medical/therapeutic 
claims. Although this requirement was not strictly enforced, none of the major companies selling 
NVPs explicitly made such claims, or any other harm-reduction claims, in labeling or advertising.  
• Although some new requirements and restrictions were applied to NVPs in August 2016, shortly 
before the end of the study time period, these did not significantly change pre-existing NVP 
marketing or sales practices. 
- FDA Deeming Rule, effective August 8, 2016 
 
 
